Updates are available Correction dated 2022-12-22
Click to view Correction: https://doi.org/10.1038/s41398-022-02288-z
-
Authors
Strom, Nora I. https://orcid.org/0000-0002-5261-8852
Smit, Dirk J. A. https://orcid.org/0000-0001-8301-8860
Silzer, Talisa
Iyegbe, Conrad
Burton, Christie L. https://orcid.org/0000-0002-8955-6528
Pool, René https://orcid.org/0000-0001-5579-0933
Lemire, Mathieu
Crowley, James J. https://orcid.org/0000-0001-9051-1557
Hottenga, Jouke-Jan https://orcid.org/0000-0002-5668-2368
Ivanov, Volen Z.
Larsson, Henrik https://orcid.org/0000-0002-6851-3297
Lichtenstein, Paul https://orcid.org/0000-0003-3037-5287
Magnusson, Patrik https://orcid.org/0000-0002-7315-7899
Rück, Christian https://orcid.org/0000-0002-8742-0168
Schachar, Russell J.
Wu, Hei Man https://orcid.org/0000-0003-1559-7586
Meier, Sandra M.
Crosbie, Jennifer
Arnold, Paul D. https://orcid.org/0000-0003-2496-4624
Mattheisen, Manuel https://orcid.org/0000-0002-8442-493X
Boomsma, Dorret I. https://orcid.org/0000-0002-7099-7972
Mataix-Cols, David https://orcid.org/0000-0002-4545-0924
Cath, Danielle
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2018-05973, 2017-00641)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (480-15-001/674, 184.021.007, 184.033.111)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U24 MH068457-06)
U.S. Department of Health & Human Services | National Institutes of Health (NIH RO1 HD042157-01A1)
- License Information
-
More Information
Article History
Received: 12 October 2022
Revised: 27 October 2022
Accepted: 2 November 2022
First Online: 15 November 2022
Change Date: 22 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41398-022-02288-z
Competing interests
: David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health, outside of the submitted work. Henrik Larsson reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. Henrik Larsson is editor-in-chief of JCPP Advances. Russell J. Schachar has consulted to E. Lilly, Highland Therapeutics and eHave. All other authors report no potential conflict of interest.
